• Bhubaneswar India
  • Contact+ 91-9938772605
  • Mon - Sat : 10:00AM - 6:00PM

Archive: May 2, 2024

AOI Mangalagiri Leads Innovation in High-Risk Breast Cancer Surgery

India, 1ST May 2024 – American Oncology Institute (AOI) in Mangalagiri proudly announces a groundbreaking advancement in the treatment of breast cancer. Recently, AOI successfully treated three high-risk patients with carcinoma breast using a novel anaesthetic technique, marking a significant milestone in cancer care.

Modified radical mastectomy (MRM) with axillary dissection is a standard surgical procedure for breast cancer treatment, typically performed under general anaesthesia. However, patients with severe comorbidities such as chronic obstructive pulmonary disease (COPD), cardiomyopathy, and chronic kidney disease face increased risks with general anaesthesia.

In response to this challenge, AOI in Mangalagiri, Vijayawada introduced a pioneering approach by utilizing Paravertebral block (PVB) along with pectoral nerves (PECS) block as the primary anaesthetic technique. This innovative method allowed the patients to undergo MRM surgery safely and successfully, without the risks associated with general anaesthesia.

Dr Kalyan Polavarapu, Surigical Oncologist, at AOI, commented, Treating patients with breast cancer who also suffer from significant comorbidities presents a unique set of challenges. Our goal is to provide the best possible care while minimizing risks and ensuring patient safety.

The treated patients included Mrs. V.L (67 years), Mrs. J.B (74 years), and Mrs. P.S (83 years), all considered very high risk for general anaesthesia due to their existing comorbidities. Despite these challenges, all three patients underwent MRM surgery without complications and were discharged within three days post-operation.

Dr Sreedevi, Consultant anesthesiologist, at AOI, commented, Paravertebral block (with ultrasound guidance ) involves administering a local anaesthetic near the spinal nerves, resulting in somatic and sympathetic nerve blockade. This technique boasts a low incidence of adverse effects, making it a safe and effective alternative for high-risk patients. By implementing Paravertebral and PECS blocks, we were able to tailor the anaesthetic approach to each patient’s individual needs, resulting in successful surgical outcomes.

Mahendra Reddy, Regional Chief Operating Officer (RCOO) of AOI, Vijayawada, expressed his pride in the hospital’s achievement, stating, “At AOI, we are committed to pushing the boundaries of cancer care and delivering innovative solutions to improve patient outcomes. The successful treatment of these high-risk breast cancer patients underscores our dedication to excellence and reinforces our position as a leader in oncology care.”

AOI remains at the forefront of cancer treatment, continually striving to provide cutting-edge therapies and personalized care to patients across the region.

Lab-grown diamond Jewellery Brand Solitario Elevates the Luxury Experience with Expansion Across India

India – May 2, 2024 – Solitario, the premier destination for luxury lab-grown diamonds has embarked on a brilliant expansion journey, reinforcing their position as the biggest players in the ethical luxury segment in India. Demonstrating a commitment to sustainability and excellence, the brand has inaugurated its 16th store at Phoenix Palladium, Chennai, within the first year of its establishment.

Founded by the visionary trio known as the Bling Boys of India – Ricky Vasandani, CEO; Satish Daryanani, Co-Founder; and Celebrity-Founder Vivek Oberoi, Solitario was conceived with the mission of introducing sustainable adornments to India, embodying the essence of responsible aesthetics.

Actor Priyamani and CEO Ricky Vasandani cutting the ribbon to Chennai's first Solitario Store

Speaking on the brand’s unparalleled growth, Ricky Vasandani, CEO of Solitario Diamonds said, “As we celebrate our journey of growth and innovation, we are proud to announce the expansion of Solitario’s retail footprint. Our mission has always been to offer discerning customers a luxury experience that aligns with their values, and our expansion allows us to bring this vision to more communities around the world.”

Solitario asserts that lab-grown diamonds possess identical physical and optical characteristics to mined diamonds while also promoting ‘good karma’ through their substantial reduction in environmental impact. While natural mining releases approximately 125 pounds of carbon per diamond, growing one in a lab emits a mere 6 pounds, aligning with Solitario’s ethos of sustainability.

This commitment combined with the quality of products has been able to alter the way the Indian market perceives and purchases diamonds. This impact is being driven by Solitario’s core team, comprising Anurag Lunia, Head of Retail Operation, Kamini Singh Head of Business Strategy and Operation and Kabir Kate, Head of Marketing.

“Our commitment lies in continuously building our brand by engaging with our audience with integrity and distinctiveness. What sets us apart and drives our growth are our designs, rooted in the timeless sophistication of European influence, with a global appeal. All pieces crafted by the brand are certified by IGI, SGL, and GIA, ensuring they are 100% authentic,” said Satish Daryanani, Co-Founder of Solitario Diamonds.

Backing this, Actor Vivek Oberoi added, “Each piece exudes a sense of refined luxury, offering not just jewellery, but a statement of individuality and sophistication. With Solitario, you’re not just wearing a piece of jewellery; you’re embracing a lifestyle of timeless allure and unparalleled elegance.”

In addition to his role as Co-Founder, Vivek is deeply engaged in the business and expansion of Solitario, serving as both the brand ambassador and its public face.

StoxBox: Research on HCL Technologies

 D. K. Mudaraddi, Research Analyst, StoxBox on HCL Technologies Ltd. Q4 FY24.

HCL Tech’s Q4FY24 revenue was impacted heavily by the seasonal weakness in the software products business despite the reversal of furloughs and incremental revenues from telecom and entertainment segment contracts. Wage hikes and normalization of products and platforms segment margin led to a significant decline in margin underperforming its peers. Leakage in discretionary business has bottomed out for HCL Tech, but there are no signs of a pickup in discretionary spending. There have been no major large deal announcements by HCL Tech in Q4FY24 which is concerning considering that its peers were able to sign mega deal MOUs during the current weak demand environment. Commentary on ER&D, Tech and Telecom vertical performance, demand scenario going forward, and ramp-up of deal wins will be key monitorable going ahead.

HCL Technologies Ltd. Q4FY24 Result First Cut – A miss on all fronts; Revenue guidance trimmed

Reported revenue grew to Rs. 28,499 crores (up 0.2% QoQ / up 7.1% YoY) in rupee terms, marginally missing market estimates of Rs. 28,557 crores.
EBIT dropped 11% QoQ / up 3.9% YoY to Rs. 5,024 crores, missing market expectations of Rs. 6,364 crores. The EBIT margin contracted to 17.6% (down 221 bps QoQ / down 55 bps YoY).
Net income grew to Rs. 3,995 crores (down 8.2% QoQ / up 0.4% YoY), missing market estimates of Rs. 4,123 crores. The PAT margin contracted to 14% (down 128 bps QoQ / down 94 bps YoY).
LTM attrition continuing recent trends declined 40bps QoQ to 12.4% in Q4FY24.
Order book recorded for Q4FY24 stood at USD 2.29 billion.
The board of directors recommended a dividend of Rs. 18 per equity share.
HCL Tech reported a headcount of 227,481 employees as on March 31, 2024, with a net addition of 2,725 employees in Q4FY24.
For FY25, HCL Tech reduced revenue guidance to 3%-5% in CC terms from 5-5.5% projected earlier, while EBIT margin guidance was retained at 18-19%.

Disclaimer/Disclaimer: This press release serves for informational purposes only and does not constitute professional advice. Any reliance on the information provided is at the reader’s discretion.